Vonvendi, Veyvondi(vonicog alfa)
Veyvondi (vonicog alfa) is a protein pharmaceutical. Vonicog alfa was first approved as Veyvondi on 2018-08-31. It has been approved in Europe to treat von willebrand diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Vonvendi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 2 | 1 | 5 | 1 | 5 | 13 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | 1 | 2 | 9 | — | 5 | 17 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | 1 | — | 1 | 3 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | 2 | — | — | 3 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | 1 | 1 | — | — | 2 |
| Coagulation protein disorders | D020147 | — | — | — | — | 2 | — | — | 2 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 1 | — | — | — | 2 | 3 |
| Hemostatic disorders | D020141 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vonicog alfa |
| INN | vonicog alfa |
| Description | Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder). It is a recombinant von Willebrand factor.
|
| Classification | Protein |
| Drug class | Hemostatic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 109319-16-6 |
| RxCUI | 1812589 |
| ChEMBL ID | CHEMBL2107873 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12872 |
| UNII ID | 5PKM8P0G5I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vonvendi – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
398 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use